Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Sponsor
Wake Forest University Health Sciences
Study ID
NCT04274166
Phase
PHASE2
Status
Withdrawn

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal antibodies. Monoclonal antibodies are proteins that recognize and attach to other specific proteins (in this case, immune system hormones called "cytokines") that your body produces. The cytokine (a "messenger" protein in the body) that secukinumab binds to and reduces the activity of is a naturally occurring cytokine called interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness), and researchers believe that IL-17A may cause symptoms PG.

Key Dates

Start date
May 31, 2021
Status verified
May 2021
Primary completion
Dec 31, 2021
Completion
Apr 30, 2022

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    2 s.c. secukinumab 150 mg injections

Primary Outcome Measure

Efficacy - Investigator Global Assessment (IGA) [ Time Frame: Screening visit ]

Related Studies